Trinity Biotech plc, a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, announced that it has secured regulatory clearances in multiple countries,  enabling the expanded rollout of its next-generation high-capacity HbA1c column system for the Premier Hb9210 analyser, which is now available in more than 10 countries, including the United States. The upgraded system significantly increases testing throughput, improves operational efficiency, and supports greater recurring revenue opportunities and margin expansion as the company strengthens its leadership position in the growing global HbA1c market.

The global laboratory HbA1c market is estimated to be currently worth over $2 billion annually and is expected to grow to exceed $3.5 billion by 2030.  This expected rise in the HbA1c market is primarily driven by the increasing prevalence of diabetes.

Designed for Trinity Biotech’s Premier Hb9210 analyser, the company’s dedicated laboratory HbA1c solution, the upgraded column system delivers up to four times the testing capacity compared to the existing column system and minimises instrument downtime through improved stability and reduced maintenance requirements. These operational gains create a more efficient workflow for clinical laboratories and support broader adoption of the platform.